Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

Blood

Volumn 127, Issue 15, 2016, Pages 1896-1906

  Paiva, Bruno ^a   Corchete, Luis A ^b   Vidriales, Maria Belen ^b   Puig, Noemi ^b   Maiso, Patricia ^a   Rodriguez, Idoia ^a   Alignani, Diego ^a   Burgos, Leire ^a   Sanchez, Maria Luz ^b   Barcena, Paloma ^b   Echeveste, Maria Asuncion ^c   Hernandez, Miguel T ^d   García Sanz, Ramón ^b   Ocio, Enrique M ^b   Oriol, Albert ^e   Gironella, Mercedes ^f   Palomera, Luis ^g   De Arriba, Felipe ^h   Gonzalez, Yolanda ⁱ   Johnson, Sarah K ^j   Epstein, Joshua ^j   Barlogie, Bart ^j   Lahuerta, Juan José ^k   Blade, Joan ^l   Orfao, Alberto ^b   Mateos, María Victoria ^b   San Miguel, Jesús F ^a   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL JOSEP TRUETA   (Spain)

^j UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; BETA7 INTEGRIN; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD79B ANTIGEN; CD81 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; GLYCOPROTEIN P 15095; HERMES ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MELPHALAN; PREDNISONE; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; CELL ADHESION MOLECULE; INTEGRIN; THALIDOMIDE;

AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CLINICAL ARTICLE; COPY NUMBER VARIATION; DOWN REGULATION; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PROCESSING; STROMA CELL; U266 CELL LINE; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; MALE; METABOLISM; MULTICENTER STUDY; NEOPLASM, RESIDUAL; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; BORTEZOMIB; CELL ADHESION MOLECULES; DEXAMETHASONE; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNOPHENOTYPING; INTEGRINS; MALE; MELPHALAN; MODELS, GENETIC; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PHENOTYPE; PLASMA CELLS; PREDNISONE; PROGNOSIS; THALIDOMIDE;

EID: 84989771015     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-665679     Document Type: Article

References (57)

1. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059-3068.
2. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076-3084.
3. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043-3051.
4. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-397.
5. Paiva B, Gutiérrez NC, Rosiñol L, et al; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-691.
6. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.
7. Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932-1935.
8. San Miguel J. Multiple myeloma: a model for scientific and clinical progress. Hematology (Am Soc Hematol Educ Program). 2014;2014(1):1-7.
9. Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010;24(8):1506-1512.
10. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 2009;69(4):1545-1552.
11. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771-4779.
12. Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164(2):233-244.
13. Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28(2):373-383.
14. Ocio EM, Fernández-Lázaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29(3):705-714.
15. Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
16. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
17. Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013;27(2):473-481.
18. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289-304.
19. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
20. Kalina T, Flores-Montero J, van der Velden VH, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
21. Paíno T, Paiva B, Sayagués JM, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia. 2015;29(5):1186-1194.
22. Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591-3598.
23. Cover TMHP. Nearest neighbor pattern classification. IEEE Trans Inf Theory. 1967;13:21-27.
24. Duda RO, Hart PE, Stork DG. Pattern Classification. New York: Wiley; 2001.
25. Pedreira CE, Costa ES, Barrena S, et al; EuroFlow Consortium. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A. 2008;73(9):834-846.
26. Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A; EuroFlow Consortium. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol. 2013;31(7):415-425.
27. Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet Genome Res. 2006;115(3-4):205-214.
28. López-Corral L, Corchete LA, Sarasquete ME, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014;99(8):1365-1372.
29. Gutiérrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21(3):541-549.
30. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77-W83.
31. Usmani SZ, Sawyer J, Rosenthal A, et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013;121(23):4753-4757.
32. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011;118(26):6860-6870.
33. Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica. 2013;98(2):279-287.
34. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332-2336.
35. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007;104(10):4048-4053.
36. Pilarski LM, Baigorri E, Mant MJ, et al. Multiple myeloma includes phenotypically defined subsets of clonotypic CD20+ B cells that persist during treatment with rituximab. Clin Med Oncol. 2008;2:275-287.
37. Chaidos A, Barnes CP, Cowan G, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121(2):318-328.
38. Paiva B, Pérez-Andrés M, Vídriales MB, et al; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas); Myeloma Stem Cell Network (MSCNET). Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25(4):697-706.
39. Murray ME, Gavile CM, Nair JR, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014;123(24):3770-3779.
40. Canella A, Cordero Nieves H, Sborov DW, et al. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 2015;6(31):31134-31150.
41. Iqbal MS, Otsuyama K, Shamsasenjan K, et al. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow. Eur J Haematol. 2009;83(4):302-312.
42. Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28(2):231-242.
43. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009;69(3):1009-1015.
44. Martínez-Viñambres E, García-Trujillo JA, Rodríguez-Martín E, Villar LM, Coll J, Roldán E. CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients. Leukemia. 2012;26(5):1098-1105.
45. Neri P, Ren L, Azab AK, et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011;117(23):6202-6213.
46. Kurata M, Nakagawa Y, Yamamoto K, Suzuki K, Kitagawa M. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. Am J Hematol. 2008;83(9):755-757.
47. Stessman HA, Mansoor A, Zhan F, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27(10):2075-2077.
48. Mateo G, Montalbán MA, Vidriales MB, et al; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737-2744.
49. Garayoa M, Garcia JL, Santamaria C, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 2009;23(8):1515-1527.
50. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
51. Ohwada C, Nakaseko C, Koizumi M, et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Haematol. 2008;80(3):245-250.
52. Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol. 2011;29(25):3427-3434.
53. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28(8):1705-1715.
54. Tagoug I, Jordheim LP, Herveau S, et al. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clin Cancer Res. 2013;19(13):3556-3566.
55. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311-5321.
56. Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28(5):1129-1131.
57. King JA, Tan F, Mbeunkui F, et al. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. Mol Cancer. 2010;9:266.